Linagliptin
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Linagliptin is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 2, 2011, and the first generic was approved Aug 31, 2021. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $1.1 billion on Linagliptin across 1.4 million claims for 275,000 beneficiaries.
Linagliptin is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $16.80 to $16.80 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$16.80 – $16.80
per EA
7d Activity
avg +0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing LINAGLIPTIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
TRADJENTA 5 MG TABLET | $16.7982 per EA | +0.01% |
TRADJENTA 5 MG TABLET | $16.7982 per EA | +0.01% |
TRADJENTA 5 MG TABLET | $16.7982 per EA | +0.01% |
Frequently Asked Questions
What is Linagliptin used to treat?
Linagliptin is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
When did Linagliptin become available as a generic?
FDA approved the first generic Linagliptin (ANDA) on Aug 31, 2021. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Linagliptin?
In 2024, Medicare Part D spent $1.1 billion on Linagliptin across 1.4 million claims for 275,000 beneficiaries.
How many Linagliptin products are on the market?
The Linagliptin drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Linagliptin?
NADAC reference prices for Linagliptin range from $16.7982 to $16.7982 per EA.
Which manufacturers make Linagliptin?
1 manufacturer lists Linagliptin in NADAC. Ranked by number of NDCs, the largest are Boehringer Ingelheim Pharmaceuticals Inc. (3).
How has the price of Linagliptin changed recently?
Over the past 7 days, 3 Linagliptin NDCs rose and 0 fell, with a market-wide average change of +0.0%.